" class="no-js "lang="en-US"> Godfrey Smith - Medtech Alert
Sunday, August 03, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Godfrey Smith | Pharmtech Focus

Godfrey Smith

About Godfrey Smith

Godfrey provides scientific leadership to the company through his role as CSO and Director. Godfrey co-founded the company in 2012 and has been responsible for its scientific development since that time. Godfrey is Professor of Cardiac Physiology with a research track record in cardiac electrophysiology.

Related Story

Drug Development

 Axol Bioscience Introduces CiPA-validated Human Stem Cell-derived Ventricular Cardiomyocytes to Help Improve Drug Discovery | Pharmtech Focus

Axol Bioscience Introduces CiPA-validated Human Stem Cell-derived Ventricular Cardiomyocytes to Help Improve Drug Discovery

June 8 2022

Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science […]